Barclays
CALA

Barclays’s Calithera Biosciences, Inc CALA Stock Holding History

Barclays’s Portfolio CALA Stock Details CALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-489
Closed -$21K – 4919
2021
Q3 		$21K Sell
489
-324
-40% -$14K ﹤0.01% 4386
2021
Q2 		$34K Sell
813
-1,955
-71% -$85.9K ﹤0.01% 4321
2021
Q1 		$134K Buy
2,768
+851
+44% +$49.5K ﹤0.01% 3885
2020
Q4 		$188K Sell
1,917
-221
-10% -$19.4K ﹤0.01% 3793
2020
Q3 		$148K Sell
2,138
-882
-29% -$77K ﹤0.01% 4034
2020
Q2 		$319K Buy
3,020
+1,096
+57% +$130K ﹤0.01% 3696
2020
Q1 		$171K Sell
1,924
-847
-31% -$101K ﹤0.01% 4424
2019
Q4 		$316K Buy
2,771
+590
+27% +$44.4K ﹤0.01% 4681
2019
Q3 		$134K Sell
2,181
-1,443
-40% -$116K ﹤0.01% 5261
2019
Q2 		$283K Buy
3,624
+2,672
+281% +$303K ﹤0.01% 4806
2019
Q1 		$128K Buy
952
+116
+14% +$12.2K ﹤0.01% 5172
2018
Q4 		$67K Sell
836
-361
-30% -$35.6K ﹤0.01% 5302
2018
Q3 		$125K Buy
1,197
+804
+205% +$76.6K ﹤0.01% 5364
2018
Q2 		$40K Sell
393
-548
-58% -$62.1K ﹤0.01% 5779
2018
Q1 		$118K Sell
941
-1,159
-55% -$181K ﹤0.01% 5261
2017
Q4 		$352K Buy
2,100
+907
+76% +$232K ﹤0.01% 4191
2017
Q3 		$376K Buy
1,193
+418
+54% +$132K ﹤0.01% 3886
2017
Q2 		$229K Sell
775
-995
-56% -$266K ﹤0.01% 4260
2017
Q1 		$409K Buy
+1,770
New +$306K ﹤0.01% 3606
2016
Q3 		– Sell
-72
Closed -$5K – 6882
2016
Q2 		$5K Buy
+72
New +$7.21K ﹤0.01% 5755
2015
Q4 		– Sell
-3
Closed – – 6775
2015
Q3 		$0 Sell
3
-8
-73% -$1.04K ﹤0.01% 7152
2015
Q2 		$1K Sell
11
-1
-8% -$232 ﹤0.01% 6943
2015
Q1 		$4K Sell
12
-21
-64% -$7.47K ﹤0.01% 6720
2014
Q4 		$13K Buy
+33
New +$8.62K ﹤0.01% 6586

Other funds holding CALA

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Barclays's CALA Position: Q4 2021 in Review

Barclays sold out of Calithera Biosciences, Inc (CALA) in Q4 2021, closing a stake of 489 shares — an estimated $21K sold.

Barclays first reported a position in CALA in Q4 2014 and held it in 24 quarters. The position peaked at $409K in Q1 2017. 55 funds tracked by Wall St. Rank hold CALA as of Q4 2021.

  • Barclays reported no remaining Calithera Biosciences, Inc position as of Q4 2021 after selling out during the quarter.
  • Barclays sold 489 Calithera Biosciences, Inc shares in Q4 2021, an estimated $21K.
  • Barclays first reported a position in Calithera Biosciences, Inc in Q4 2014 and held it in 24 quarters.
  • Barclays's Calithera Biosciences, Inc position peaked at $409K in Q1 2017.
  • 55 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q4 2021.

Based on Barclays's 13F filing for Q4 2021, filed 14 Feb 2022.